As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of CytoMed Therapeutics Ltd. The largest reported stake is Choo Chee Kong's, at 25.17%. 5 filings are on record since October 29, 2025 (Schedule 13D/A, October 16, 2026).
Sell to companies like CytoMed Therapeutics Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: mDR LTD · Sole voting: 1,191,523 · Shared voting: 0 · Sole dispositive: 1,191,523 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-23
- · Reporting person: Choo Chee Kong · Sole voting: 928,686 · Shared voting: 3,773,291 · Sole dispositive: 928,686 · Shared dispositive: 3,773,291 · SCHEDULE 13D/A, 2026-10-16
- · Holder: Choo Chee Kong · Percent: 24.92% · SCHEDULE 13D/A
- · Holder: Choo Chee Kong · Percent: 24.3% · SCHEDULE 13D/A
- · Holder: Choo Chee Kong · Percent: 22.05% · SCHEDULE 13D/A
CytoMed Therapeutics Ltd has 5 Schedule 13D or 13G filings on record since 2025-10-29. 2 holders' latest filing reports 5% or more of ordinary shares, no par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 25.17% | 3,003,996 | SCHEDULE 13D/A, 2026-10-16 | 2026-10-12 | |
| mDR LTD | 9.98% | 1,191,523 | SCHEDULE 13G/A, 2026-10-23 | 2026-10-12 |
Holding shares or following this stake? See who's behind CytoMed Therapeutics Ltd and the warning signs.
Free to see. No signup.
Keep reading
More on CytoMed Therapeutics Ltd and the records around it.
CytoMed Therapeutics Ltd elsewhere on the record
Watch CytoMed Therapeutics Ltd
Get an email when CytoMed Therapeutics Ltd files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on CytoMed Therapeutics Ltd?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on CytoMed Therapeutics Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CytoMed Therapeutics Ltd covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Choo Chee Kong | 928,686 | 3,773,291 | 928,686 | 3,773,291 | SCHEDULE 13D/A, 2026-10-16 |
| mDR LTD | 1,191,523 | 0 | 1,191,523 | 0 | SCHEDULE 13G/A, 2026-10-23 |
The latest filing identifies CytoMed Therapeutics Ltd by CUSIP Y1R80M106 and gives its principal executive office as #08-22 One Commonwealth, 1 Commonwealth Lane, Singapore (SCHEDULE 13G/A, 2026-10-23).
Source of funds (Item 3)
PF; Between October 12, 2026 and October 15, 2026, the Reporting Person acquired an aggregate of 29,250 Ordinary Shares in open market purchases on the Nasdaq Capital Market for an aggregate purchase price of approximately $25,117.35, settled through the Reporting Person's brokerage account with personal funds.Choo Chee Kong, SCHEDULE 13D/A, 2026-10-16
Purpose of Transaction (Item 4)
Choo Chee Kong
Mr. Choo Chee Kong has acquired all of the Ordinary Shares beneficially owned by him (1) in exchange for capital contributions to the Issuer or (2) through public purchases on the open market with his personal funds for investment purposes. The Reporting Person serves as Chairman of the Issuer and is a member of the board of directors of the Issuer and, as a result, may be asked to vote on or discuss matters related to items (a) through (j) of this Item 4 of Schedule 13D with representatives of the Issuer and others. Except as may be set forth herein, the Reporting Person has no current intention, plan or proposal with respect to items (a) through (j) of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-10-16
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-29 | Choo Chee Kong | 22.05% | SCHEDULE 13D/A |
| 2026-07-24 | Choo Chee Kong | 24.3% | SCHEDULE 13D/A |
| 2026-10-13 | Choo Chee Kong | 24.92% | SCHEDULE 13D/A |
| 2026-10-16 | Choo Chee Kong | 25.17% | SCHEDULE 13D/A |
| 2026-10-23 | mDR LTD | 9.98% | SCHEDULE 13G/A |
Questions about who owns CytoMed Therapeutics Ltd
Who owns CytoMed Therapeutics Ltd?
On this page, 2 holders' latest ownership filings report 5% or more of CytoMed Therapeutics Ltd: Choo Chee Kong (25.17%, Schedule 13D/A, filed 2026-10-16) and mDR LTD (9.98%, Schedule 13G/A, filed 2026-10-23).
Who are the largest shareholders of CytoMed Therapeutics Ltd?
By the share each holder's latest filing reports, the largest holders of CytoMed Therapeutics Ltd on this page are Choo Chee Kong (25.17%) and mDR LTD (9.98%).
When did Choo Chee Kong buy into CytoMed Therapeutics Ltd?
The filings give report dates, not purchase dates. The earliest filing from Choo Chee Kong on this page is the Schedule 13D/A, filed 2025-10-29, reporting 22.05%; its latest, Schedule 13D/A filed 2026-10-16, reports 25.17%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for CytoMed Therapeutics Ltd. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.